Urakçı Zuhat, Oruc Zeynep, Kömek Halil, Ebinç Senar, Pirinççi Esra, Kalkan Ziya, Taşdemir Bekir, Kaplan Muhammet Ali, Küçüköner Mehmet, Işıkdoğan Abdurrahman
Dicle University, Faculty of Medicine, Department of Medical Oncology - Diyarbakır, Türkiye.
Gazi Yasargil Training and Research Hospital, Department of Nuclear Medicine - Diyarbakır, Türkiye.
Rev Assoc Med Bras (1992). 2025 Jun 2;71(4):e20240411. doi: 10.1590/1806-9282.20240411. eCollection 2025.
The aim of this study was to compare the prognostic value of inflammatory indices, including the prognostic nutritional index, advanced lung cancer inflammation index, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, Glasgow Prognostic Score, and C-reactive protein/albumin ratio, in patients with metastatic non-small cell lung cancer and to determine whether any of the indices are correlated.
The demographic, clinicopathological, and laboratory data of 179 patients with metastatic non-small cell lung cancer who presented to our medical oncology clinic between 2014 and 2021 were retrospectively obtained from the hospital database system.
Among the inflammatory indices, C-reactive protein/albumin ratio (p=0.002), advanced lung cancer inflammation index (p=0.04), and neutrophil/lymphocyte ratio (p=0.008) were associated with overall survival. Multivariate overall survival analysis showed that Eastern Cooperative Oncology Group Performance Status score (HR 1.37; 95%CI 1.06-1.77; p=0.016) and C-reactive protein/albumin ratio (HR 1.13; 95%CI 1.03-1.24; p=0.01) were independent prognostic factors associated with overall survival. Patients with a high and low C-reactive protein/albumin ratio differed statistically significantly in terms of gender, histopathological subtype, history of smoking, and metastatic site (p<0.05). Correlation analysis showed that C-reactive protein/albumin ratio was negatively correlated with advanced lung cancer inflammation index (r=-0.433, p<0.001) and positively correlated with the other four indices (neutrophil/lymphocyte ratio: r=0.368, p<0.001; platelet/lymphocyte ratio: r=0.321, p<0.001; Glasgow Prognostic Score: r=0.537, p<0.001; and prognostic nutritional index: r=0.223, p=0.003).
Our findings show that among the investigated inflammatory indices, C-reactive protein/albumin ratio has the highest prognostic value in patients with metastatic non-small cell lung cancer.
本研究旨在比较包括预后营养指数、晚期肺癌炎症指数、中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值、格拉斯哥预后评分及C反应蛋白/白蛋白比值在内的炎症指标对转移性非小细胞肺癌患者的预后价值,并确定这些指标之间是否存在相关性。
回顾性收集2014年至2021年期间在我院肿瘤内科就诊的179例转移性非小细胞肺癌患者的人口统计学、临床病理及实验室数据,数据来源于医院数据库系统。
在炎症指标中,C反应蛋白/白蛋白比值(p = 0.002)、晚期肺癌炎症指数(p = 0.04)及中性粒细胞/淋巴细胞比值(p = 0.008)与总生存期相关。多因素总生存分析显示,东部肿瘤协作组体能状态评分(HR 1.37;95%CI 1.06 - 1.77;p = 0.016)及C反应蛋白/白蛋白比值(HR 1.13;95%CI 1.03 - 1.24;p = 0.01)是与总生存期相关的独立预后因素。C反应蛋白/白蛋白比值高和低的患者在性别、组织病理学亚型、吸烟史及转移部位方面差异有统计学意义(p < 0.05)。相关性分析显示,C反应蛋白/白蛋白比值与晚期肺癌炎症指数呈负相关(r = -0.433,p < 0.001),与其他四个指标呈正相关(中性粒细胞/淋巴细胞比值:r = 0.368,p < 0.001;血小板/淋巴细胞比值:r = 0.321,p < 0.001;格拉斯哥预后评分:r = 0.537,p < 0.001;预后营养指数:r = 0.223,p = 0.003)。
我们的研究结果表明在所研究的炎症指标中,C反应蛋白/白蛋白比值对转移性非小细胞肺癌患者具有最高的预后价值。